Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 6/20 | 0.52 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | ABCB4 | P21439 | 1/20 | 0.52 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.52 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.52 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.52 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13719558 | 1.00 | LPAR1 (0.52) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL6246 | 1.00 | LPAR1 (0.52) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL7711 | 0.92 | LPAR1 (0.61) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL7069 | 0.92 | LPAR1 (0.61) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL6507 | 0.92 | LPAR1 (0.61) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL5866 | 0.80 | LPAR1 (0.51) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL7215 | 0.80 | LPAR1 (0.51) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL6910 | 0.80 | LPAR1 (0.51) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL6612 | 0.80 | LPAR1 (0.58) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL4996 | 0.80 | ABCC3 (0.48) | LPAR1ABCC3ABCC4ABCB11CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624182-B2 | Compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| EP-2483252-B1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20150329502-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-9090573-B2 | Compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20120289522-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC. | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289522-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885ABCC3 3151/4885ABCC4 3263/4885 |
| US-20150329502-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885ABCC3 3151/4885ABCC4 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.